Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245496 | 1.00 | MTNR1A (0.36) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL23992181 | 1.00 | MTNR1A (0.36) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL10062233 | 0.84 | MTNR1A (0.44) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL9407517 | 0.79 | LMNA (0.37) | HIF1A | |
| SCHEMBL21231186 | 0.77 | MTNR1A (0.37) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL21452804 | 0.76 | MTNR1A (0.39) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL21452803 | 0.76 | MTNR1A (0.39) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL13779167 | 0.76 | MTNR1A (0.39) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL21452806 | 0.76 | MTNR1A (0.39) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL13918161 | 0.76 | MTNR1A (0.39) | MTNR1AMTNR1BKDM4EMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | MTNR1A 276/4885MTNR1B 178/4885KDM4E 2973/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | MTNR1A 276/4885MTNR1B 178/4885KDM4E 2973/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | MTNR1A 275/4885MTNR1B 171/4885KDM4E 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.